Student Research Committee, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Department of Nutrition, Zahedan University of Medical Sciences, Zahedan, Iran.
Phytother Res. 2020 Jul;34(7):1587-1598. doi: 10.1002/ptr.6637. Epub 2020 Feb 18.
The therapeutic potential of green tea as a rich source of antioxidants and anti-inflammatory compounds has been investigated by several studies. The present study aimed to systematically review and analyze randomized clinical trials (RCTs) assessing the effects of green tea, catechin, and other forms of green tea supplementation on levels of liver enzymes. PubMed, SCOPUS, EMBASE, and Cochrane databases were searched until February 2019. All RCTs investigating the effect of green tea or its catechin on liver enzymes including alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin were included. A total of 15 RCTs were included. The overall effect of green tea on liver enzymes was nonsignificant (ALT [Standardized mean difference (SMD)= -0.17, CI -0.42 to 0.08, p = .19], AST [SMD = -0.07, CI -0.43 to 0.29, p = .69], and ALP [SMD = -0.17, CI -0.45 to 0.1, p = .22]). However, subgroup analyses showed that green tea reduced the levels of liver enzymes in participants with nonalcoholic fatty liver disease (NAFLD) but in healthy subjects, a small significant increase in liver enzymes was observed. In conclusion, the results of this study suggest that the effect of green tea on liver enzymes is dependent on the health status of individuals. While a moderate reducing effect was observed in patients with NAFLD, in healthy subjects, a small increasing effect was found.
绿茶作为一种富含抗氧化剂和抗炎化合物的治疗潜力已被多项研究证实。本研究旨在系统地回顾和分析评估绿茶、儿茶素和其他形式的绿茶补充剂对肝脏酶水平影响的随机临床试验(RCT)。检索了 PubMed、SCOPUS、EMBASE 和 Cochrane 数据库,检索时间截至 2019 年 2 月。所有研究绿茶或其儿茶素对包括丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)和胆红素在内的肝脏酶影响的 RCT 均被纳入。共纳入 15 项 RCT。绿茶对肝脏酶的总体影响无统计学意义(ALT [标准化均数差(SMD)=-0.17,CI -0.42 至 0.08,p = 0.19],AST [SMD = -0.07,CI -0.43 至 0.29,p = 0.69]和 ALP [SMD = -0.17,CI -0.45 至 0.1,p = 0.22])。然而,亚组分析表明,绿茶可降低非酒精性脂肪性肝病(NAFLD)患者的肝脏酶水平,但在健康受试者中,观察到肝脏酶的微小显著升高。总之,本研究结果表明,绿茶对肝脏酶的影响取决于个体的健康状况。在 NAFLD 患者中观察到适度的降低作用,而在健康受试者中发现了微小的升高作用。